Strattera, a non-stimulant medication for the treatment of ADHD, is a medication primarily used to treat attention deficit hyperactivity disorder (ADHD). It is a non-stimulant and selective norepinephrine reuptake inhibitor (SNRI). The drug acts by increasing the levels of norepinephrine in the brain. Norepinephrine is a neurotransmitter, a natural substance that regulates mood, attention, and impulse control. Strattera belongs to the class of norepinephrine reuptake inhibitors, which can work in the brain by blocking the reuptake of norepinephrine.
Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor that works by increasing the levels of norepinephrine in the brain.
Strattera is available in various dosages ranging from 25 mg to 100 mg per day. It is essential to follow the prescribed dosage regimen to maximize its benefits and minimize the risk of side effects.
In some cases, a healthcare provider may prescribe Strattera for an initial assessment, such as a comprehensive evaluation and assessment of the patient's overall health status.
Strattera may cause side effects, although not everyone will experience them. Common side effects may include:
More severe side effects are rare but may include the following:
Strattera has a broad range of benefits compared to other ADHD medications, making it a valuable treatment option for patients with ADHD. However, it is essential to follow the recommended dosage and dosage schedule carefully to maximize its benefits and minimize the risk of side effects.
Strattera, a non-stimulant medication primarily used for the treatment of ADHD, has revolutionized the treatment of attention deficit hyperactivity disorder (ADHD) with its non-stimulant properties. Unlike traditional stimulant medications that can be administered orally, Strattera works by inhibiting the reuptake of norepinephrine, a neurotransmitter involved in attention and behavior regulation. By reducing the release of dopamine, Strattera helps improve attention, impulse control, and impulse control in individuals with ADHD.
Understanding the role of Strattera in ADHD management can help individuals make informed decisions about their treatment options. By addressing the underlying cause of ADHD, Strattera offers individuals the opportunity to improve their symptoms, increase their overall quality of life, and improve their overall quality of life. Additionally, Strattera is gaining traction among healthcare providers as it becomes more widely available in clinical settings.
Strattera, generically known as atomoxetine, is a non-stimulant medication primarily used for the treatment of ADHD. Unlike stimulant medications that can be administered orally, Strattera works by inhibiting the reuptake of norepinephrine, a neurotransmitter involved in attention and behavior regulation. This action helps to improve attention span, increase focus, and reduce impulsivity.
Strattera works by increasing norepinephrine levels in the brain, which can enhance attention and reduce hyperactivity in individuals with ADHD. Specifically, Strattera increases norepinephrine availability by blocking the reuptake of norepinephrine, effectively inhibiting the reabsorption of norepinephrine in the brain. This mechanism of action not only helps to improve attention span, increase focus, and reduce impulsivity but also can improve impulse control and cognitive function.
Clinical studies have demonstrated the effectiveness of Strattera in managing ADHD symptoms, including:
Strattera can be prescribed by healthcare providers as part of a comprehensive treatment plan that includes psychotherapy, counseling, and support groups. It’s important to note that Strattera should only be used as prescribed by a healthcare professional, as misuse can lead to adverse effects or inadequate treatment.
In clinical settings, Strattera has demonstrated significant efficacy in reducing ADHD symptoms. Clinical studies have shown that Strattera is well-tolerated and has a positive impact on behavior, impulse control, and impulse management in children and adults with ADHD. Additionally, Strattera has shown effectiveness in reducing impulsivity and hyperactivity in adults with ADHD, with outcomes such as achievement and concentration reported to be generally favorable (see).
While Strattera is effective, it’s important to understand that Strattera may not be as effective as stimulant medications in managing ADHD symptoms. Additionally, Strattera is not suitable for everyone, and its use should be individualized. It’s essential to communicate openly with healthcare providers and support groups to ensure that Strattera is a safe and effective treatment option for individuals with ADHD.
The cost of Strattera varies depending on the dosage and specific healthcare needs of the individual. Some healthcare providers may charge a fraction of the cost of Strattera for its initial indications, while others may require up to a 30% to 60% increase in the dosage or a higher cost per month. It’s crucial to consult with your healthcare provider to determine the most appropriate dosage for your specific needs.
In summary, Strattera is a cornerstone in the management of ADHD and should be prescribed by a healthcare professional for those considering its use as part of a comprehensive treatment plan. By understanding its mechanism of action, benefits, and potential side effects, healthcare providers can provide more personalized recommendations for individuals seeking effective treatment options.
Adderall (atomoxetine) -The introduction and management of ADHD medications has been a significant factor in the success of healthcare providers and patients. By understanding the mechanism of action, benefits, and potential side effects of Strattera, healthcare providers can make informed decisions about prescribing Strattera to meet the needs of individuals with ADHD.
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Add to Cartoons.ananila.com/ananila_photos.ashxHealthylife contains generic versions of several ADHD medications, including Atomoxetine (60mg), which is approved by the US Food and Drug Administration (US FDA) as a first-line treatment for ADHD. If you are experiencing symptoms of ADHD, such as forgetfulness, distractibility, impulsive thinking, inability to concentrate, and/or repetitive behaviors, seek immediate medical attention.
List Price/Savings $14.99$0.99
Adderall (60mg)
Adderall is used to treat an enlarged prostate gland (benign prostatic hyperplasia-BPH), which is a common condition that affects over two million men in the United States. When a man has BPH, his prostate gland becomes larger and causes symptoms of urinary problems such as frequent urination, weak urine stream, and inability to pass urine. These symptoms can cause difficulty urinating, difficulty urinating due to enlarged prostate, and lower urinary tract symptoms such as frequent urge to urinate, weak urine stream, and inability to pass urine. If you are experiencing symptoms of BPH, such as chest pain or pressure, chest pain, difficulty urinating, and pressure in your lower back, you should consult a doctor.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$40.95
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Healthylife Product InformationRead the, or if applicable, the patient information Leaflet on file. If you have any questions or concerns, please review theHealthylife Online Pharmacy https://www.healthylife.com.au/product/all/Healthylife provides iambicaddat (LINZOPHORT) ASA, which contains phenylalanine and is available in various forms, including oral tablets, syrup and capsule. iambicaddat is also available as the combination product iambicaddat plus phenylalanine. iambicaddat product description and general information on the iambicaddat product line are provided for your convenience.
Healthylife Pharmacy https://www.healthylife.com.au/product/iambicaddatHealthylife offers a Patient Information Leaflet on file with your Card.
INDIANAPOLIS, April 28, 2017 /PRNewswire/ --
Pfizer Inc. (NYSE: PFE) today announced the launch of Strattera® (atomoxetine hydrochloride) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Strattera was launched on November 30, 2017, on theNYSEPFE(NYSE: PFE).
Under the terms of the agreement, Pfizer will acquire the rights to market Strattera to Eli Lilly and Company (NYSE: LLY) and Apotex (NYSE: AMR) for the treatment of ADHD. Strattera is an FDA approved treatment for ADHD, which includes hyperactivity, inattention, impulsivity, and hyperactivity/impulsivity disorders. The generic version of Strattera will be marketed to patients in Canada by Eli Lilly Canada Inc. for treatment of ADHD and in Australia by Apotex Canada Inc. for treatment of ADHD.
Pfizer's agreement with Lilly and Company to acquire Strattera will allow Pfizer to launch its atomoxetine drug for ADHD in the US in 2017. This will be the first drug to launch in the US to treat ADHD.
Strattera is available in the United States under various brand names, including Adderall, Adderine, Adderose, Cialis, Adderiva, and Strattera. Strattera is a registered trademark of Eli Lilly and Company.
Strattera is a registered trademark of Pfizer.
Source: Pfizer
CONTACTS:,,,Media: David Carr, Ph. D.,Media contact:
David Carr, Ph.Richard L. Kieber, Ph.D.
Stade de France Pharmacy